{"id":441883,"date":"2021-02-23T08:33:23","date_gmt":"2021-02-23T13:33:23","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=441883"},"modified":"2021-02-23T08:33:23","modified_gmt":"2021-02-23T13:33:23","slug":"cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\/","title":{"rendered":"Cassava Sciences to Present at\u00a0SVB Leerink Global Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">AUSTIN, Texas, Feb.  23, 2021  (GLOBE NEWSWIRE) &#8212; Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer\u2019s disease, has been invited to present at the 10th Annual SVB Leerink Global Healthcare Conference.<\/p>\n<p align=\"justify\">Remi Barbier, President &amp; CEO, and Eric Schoen, Chief Financial Officer, are scheduled to present on Thursday, February 25<sup>th<\/sup> at 2:20pm Eastern time and will participate in virtual one-on-one meetings with institutional analysts and investors throughout the conference.<\/p>\n<p align=\"justify\">The live webcast of Cassava Sciences\u2019 presentation can be accessed under the \u2018Investors\u2019 tab at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hL01a6LC4_x6mNZR916RNa9o2O6kh9ummv2dh23T1kKE-r_n6B7g3udK3V1Dz5Ggc-9oYvdslK_56LXly0KLu2LkAZU-kvLFHp1SqhqbcOo=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.CassavaSciences.com<\/a> and will be available for replay through May 26, 2021.<\/p>\n<p align=\"justify\">\n        <strong>About Alzheimer&#8217;s Disease <\/strong><br \/>\n        <br \/>Alzheimer\u2019s disease is a progressive brain disorder that destroys memory and thinking skills. Currently, there are no drug therapies to halt Alzheimer\u2019s disease, much less reverse its course. As of 2020, there were approximately 50 million people worldwide living with dementia, a figure expected to increase to 150 million by 2050.<sup>1<\/sup> The annual global cost of dementia is now above $1 trillion, according to <em>Alzheimer\u2019s Disease International<\/em>, a charitable organization.<\/p>\n<p align=\"justify\">\n        <strong>About Simufilam, the Company\u2019s Lead Drug Candidate<\/strong><br \/>\n        <br \/>Simufilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain. Altered FLNA in the brain disrupts the normal function of neurons, leading to Alzheimer\u2019s pathology, neurodegeneration and neuroinflammation. The underlying science for simufilam is published in peer-reviewed journals, including <em>Journal of Neuroscience<\/em>, <em>Neurobiology of Aging<\/em>, <em>Journal of Biological Chemistry, Neuroimmunology and Neuroinflammation <\/em>and<em> Journal of Prevention of Alzheimer\u2019s Disease. <\/em>Cassava Sciences is also developing an investigational diagnostic, called SavaDx, to detect Alzheimer\u2019s disease with a simple blood test. Simufilam and SavaDx were both developed in-house. Both product candidates are substantially funded by peer-review research grant awards from the National Institutes of Health (NIH). Cassava Sciences owns worldwide development and commercial rights to its research programs in Alzheimer\u2019s disease, and related technologies, without royalty obligations to any third party.<\/p>\n<p align=\"justify\">\n        <strong>About Cassava Sciences, Inc.<\/strong><br \/>\n        <br \/>Cassava Sciences\u2019 mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer\u2019s disease. For more information, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QyZ7mt3oVeqbtJWemToIWDkOXyKGTK5ipwPhLa7yWNd0B_CAgIaFOIXlBfKaH7lOltiaLaGiXIJU-UQr6mAOZwwBPV8GsaZ87mYopp6xAfIEy0sd5rrL-vD915SGLUKh\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.CassavaSciences.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>For More Information Contact:<\/strong><br \/>\n        <br \/>Eric Schoen, Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-JKiXhZJ3UUdM2wl38DLw7VffiMV939PuQ2DwJB_VF-EDwOKR8rbR4OfQ_2ejztlUJdolspy9Wk47TjH98yyCv21_4edo1IEvecdYkK0bGpA85Nc7-IjqcaZeVXi-95o\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">eschoen@CassavaSciences.com<\/a><br \/>(512) 501-2450<\/p>\n<p align=\"center\" \/>\n<p>\n        <em>_______________<br \/><\/em><br \/>\n        <sup><br \/>\n          <em>1<\/em><br \/>\n        <\/sup><br \/>\n        <em> Alzheimer&#8217;s Disease International<\/em><br \/>\n        <em>,<\/em><br \/>\n        <em>Dementia Statistics<\/em><br \/>\n        <em>, available on-line<\/em><br \/>\n        <em> and accessed February 20, 2021<\/em><br \/>\n        <em>:<br \/><\/em><br \/>\n        <em>https:\/\/www.alzint.org\/about\/dementia-facts-figures\/dementia-statistics\/<\/em>\n      <\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzE0OCMzOTg4MjQ0IzIwMjc4MTI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/0d287c8e-6a07-4117-bc3d-68d40cebdcd1\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AUSTIN, Texas, Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer\u2019s disease, has been invited to present at the 10th Annual SVB Leerink Global Healthcare Conference. Remi Barbier, President &amp; CEO, and Eric Schoen, Chief Financial Officer, are scheduled to present on Thursday, February 25th at 2:20pm Eastern time and will participate in virtual one-on-one meetings with institutional analysts and investors throughout the conference. The live webcast of Cassava Sciences\u2019 presentation can be accessed under the \u2018Investors\u2019 tab at www.CassavaSciences.com and will be available for replay through May 26, 2021. About Alzheimer&#8217;s Disease Alzheimer\u2019s disease is a progressive brain disorder that destroys memory and thinking skills. Currently, there are &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cassava Sciences to Present at\u00a0SVB Leerink Global Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-441883","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cassava Sciences to Present at\u00a0SVB Leerink Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cassava Sciences to Present at\u00a0SVB Leerink Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AUSTIN, Texas, Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer\u2019s disease, has been invited to present at the 10th Annual SVB Leerink Global Healthcare Conference. Remi Barbier, President &amp; CEO, and Eric Schoen, Chief Financial Officer, are scheduled to present on Thursday, February 25th at 2:20pm Eastern time and will participate in virtual one-on-one meetings with institutional analysts and investors throughout the conference. The live webcast of Cassava Sciences\u2019 presentation can be accessed under the \u2018Investors\u2019 tab at www.CassavaSciences.com and will be available for replay through May 26, 2021. About Alzheimer&#8217;s Disease Alzheimer\u2019s disease is a progressive brain disorder that destroys memory and thinking skills. Currently, there are &hellip; Continue reading &quot;Cassava Sciences to Present at\u00a0SVB Leerink Global Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-23T13:33:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzE0OCMzOTg4MjQ0IzIwMjc4MTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cassava Sciences to Present at\u00a0SVB Leerink Global Healthcare Conference\",\"datePublished\":\"2021-02-23T13:33:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\\\/\"},\"wordCount\":416,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzE0OCMzOTg4MjQ0IzIwMjc4MTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\\\/\",\"name\":\"Cassava Sciences to Present at\u00a0SVB Leerink Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzE0OCMzOTg4MjQ0IzIwMjc4MTI=\",\"datePublished\":\"2021-02-23T13:33:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzE0OCMzOTg4MjQ0IzIwMjc4MTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzE0OCMzOTg4MjQ0IzIwMjc4MTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cassava Sciences to Present at\u00a0SVB Leerink Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cassava Sciences to Present at\u00a0SVB Leerink Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Cassava Sciences to Present at\u00a0SVB Leerink Global Healthcare Conference - Market Newsdesk","og_description":"AUSTIN, Texas, Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer\u2019s disease, has been invited to present at the 10th Annual SVB Leerink Global Healthcare Conference. Remi Barbier, President &amp; CEO, and Eric Schoen, Chief Financial Officer, are scheduled to present on Thursday, February 25th at 2:20pm Eastern time and will participate in virtual one-on-one meetings with institutional analysts and investors throughout the conference. The live webcast of Cassava Sciences\u2019 presentation can be accessed under the \u2018Investors\u2019 tab at www.CassavaSciences.com and will be available for replay through May 26, 2021. About Alzheimer&#8217;s Disease Alzheimer\u2019s disease is a progressive brain disorder that destroys memory and thinking skills. Currently, there are &hellip; Continue reading \"Cassava Sciences to Present at\u00a0SVB Leerink Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-23T13:33:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzE0OCMzOTg4MjQ0IzIwMjc4MTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cassava Sciences to Present at\u00a0SVB Leerink Global Healthcare Conference","datePublished":"2021-02-23T13:33:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\/"},"wordCount":416,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzE0OCMzOTg4MjQ0IzIwMjc4MTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\/","name":"Cassava Sciences to Present at\u00a0SVB Leerink Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzE0OCMzOTg4MjQ0IzIwMjc4MTI=","datePublished":"2021-02-23T13:33:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzE0OCMzOTg4MjQ0IzIwMjc4MTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzE0OCMzOTg4MjQ0IzIwMjc4MTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-to-present-at-svb-leerink-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cassava Sciences to Present at\u00a0SVB Leerink Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/441883","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=441883"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/441883\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=441883"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=441883"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=441883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}